Cargando…

Tipifarnib in the treatment of acute myeloid leukemia

Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra®), a non-peptidomimetic compe...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Xavier, Elhamri, Mohamed
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721284/
https://www.ncbi.nlm.nih.gov/pubmed/19707311
_version_ 1782170174240063488
author Thomas, Xavier
Elhamri, Mohamed
author_facet Thomas, Xavier
Elhamri, Mohamed
author_sort Thomas, Xavier
collection PubMed
description Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra®), a non-peptidomimetic competitive FTI, showed great potency against leukemic cells. Although it has recently demonstrated clinical responses in adults with refractory and relapsed acute myeloid leukemia (AML), and in older adults with newly diagnosed poor-risk AML, its activity was far less than anticipated. However, it appears that tipifarnib as a single agent may be important in selected groups of patients. Much remains to be learned to optimize such therapy in patients with AML. To this end, trials that combine tipifarnib with cytotoxics are ongoing.
format Text
id pubmed-2721284
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27212842009-08-25 Tipifarnib in the treatment of acute myeloid leukemia Thomas, Xavier Elhamri, Mohamed Biologics Review Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra®), a non-peptidomimetic competitive FTI, showed great potency against leukemic cells. Although it has recently demonstrated clinical responses in adults with refractory and relapsed acute myeloid leukemia (AML), and in older adults with newly diagnosed poor-risk AML, its activity was far less than anticipated. However, it appears that tipifarnib as a single agent may be important in selected groups of patients. Much remains to be learned to optimize such therapy in patients with AML. To this end, trials that combine tipifarnib with cytotoxics are ongoing. Dove Medical Press 2007-12 2007-12 /pmc/articles/PMC2721284/ /pubmed/19707311 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Thomas, Xavier
Elhamri, Mohamed
Tipifarnib in the treatment of acute myeloid leukemia
title Tipifarnib in the treatment of acute myeloid leukemia
title_full Tipifarnib in the treatment of acute myeloid leukemia
title_fullStr Tipifarnib in the treatment of acute myeloid leukemia
title_full_unstemmed Tipifarnib in the treatment of acute myeloid leukemia
title_short Tipifarnib in the treatment of acute myeloid leukemia
title_sort tipifarnib in the treatment of acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721284/
https://www.ncbi.nlm.nih.gov/pubmed/19707311
work_keys_str_mv AT thomasxavier tipifarnibinthetreatmentofacutemyeloidleukemia
AT elhamrimohamed tipifarnibinthetreatmentofacutemyeloidleukemia